With almost 30 years' experience of PET and PET-CT scanning and now also PET-MR, the King's College London & Guy's and St Thomas' PET Centre provides PET services for referred patients at a local and national level and performs clinically related research. We scan over 8000 patients per year. Enhancements and refurbishments over the last five years let us be there for our patients at every step of the experience and make it as smooth and comfortable as possible.
Our PET Centre is a centre of excellence with an international reputation for delivering the best patient care, highest quality academic research, and training. We strive to make a difference for the patients we scan, and via the research we perform.
Our mission is to perform basic, translational and applied clinical PET research across all specialties including oncology, neurology/psychiatry, and cardiology. We welcome work with external collaborators, including industry. We aim to obtain the best possible quality and reliability for all studies we perform.
The Centre develops exciting PET methodology (e.g. PET-MR), and also performs cutting-edge research into innovative radiochemistry using our in-house cyclotron and our wide range of multidisciplinary expertise.
Upcoming Short Course in Simultaneous PET-MR: Science and Practice
This short course will take place online this year on the 19th to 21st May. As usual, the first day will be separated for participans with PET and MRI backgrounds to bring them up to speed with the other modality. On days two and three, there will be virtual scanner visits, talks, active learning sessions, workshops and "reading with the experts" sessions as well as talks on the use of PET-MR in the clinical areas of cardiology, neuroscience/neurology and oncology, not to forget industry perspectives. The course is accredited for CPD.
Encouraging Results in a Phase 2 Trial in Patients with an Ultra-Rare Bone Disease
Regeneron have announced encouraging results from a study evaluating a novel drug, garetosmab, which has shown potential as a treatment for patients with fibrodysplasia ossificans progressive (FOP). FOP is an ultra-rare progressive genetic disorder in which muscle and tissue are gradually replaced by bone. Patients enrolled on the study have visited the PET Centre to have 18F-NaF scans to investigate how well the drug is working.
Click here to read the press release from Regeneron.